In 2012, the company became an Ockham Development Group company and in 2014 was acquired by Chiltern with Clare moving into the role of Chief Development Officer. Chiltern is a leading, global contract research organisation focused on providing expertise, engagement, and tailored, responsive solutions to meet the demands of biotech and pharmaceutical partners of all sizes.
For Roslin BioCentre, in the heart of the Edinburgh Science Triangle, the transition from Nexus Oncology to becoming a part of global leader Chiltern is a fine example of the graduation of a company and the level of support the science park provides from incubation stage through periods of extended growth and development.
Malcolm Bateman, Chair of Roslin BioCentre, said:
“It has been a pleasure to support the team over the years, accommodating the changing needs as the business has progressed through various stages and transformed since 1999.”
Chiltern is a leading, global, mid-sized contract research organisation (CRO) that listens to client needs in order to customise solutions for the biopharma industry. With 33 years in service, Chiltern leads the industry in oncology, source, and biopharmaceutics development. Chiltern’s 2,200 engaged professionals work across 45 countries to deliver flexible, responsive solutions that are “Designed Around You”.
Roslin BioCentre is a world-leading ‘centre of excellence’ for life sciences at the heart of the Edinburgh Science Triangle. The science park is renowned as the birthplace of ‘Dolly’ the sheep and is the location of choice for a wide range of successful companies. It offers laboratory and office facilities providing practical property solutions to research and development organisations in the biotechnology and life sciences industries.
Roslin BioCentre is located in Midlothian, near to Edinburgh and with excellent local, national and international transport links.
For further information on facilities and services, please contact:
t: 44 (0)131 200 6400